These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 26502722

  • 1. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 2. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 3. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan 01; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 4. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.
    Liver Int; 2017 Jul 01; 37(7):1047-1055. PubMed ID: 28066978
    [Abstract] [Full Text] [Related]

  • 5. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.
    Oncologist; 2014 Apr 01; 19(4):394-402. PubMed ID: 24652387
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Apr 01; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 7. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014 Apr 01; 32(6):705-10. PubMed ID: 25376287
    [Abstract] [Full Text] [Related]

  • 8. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I, Scionti A, Mismas V, Masi G, Vivaldi C, Bartolozzi C, Sacco R.
    Oncology; 2014 Apr 01; 86(4):191-8. PubMed ID: 24800837
    [Abstract] [Full Text] [Related]

  • 9. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    Tovoli F, Renzulli M, Negrini G, Brocchi S, Ferrarini A, Andreone A, Benevento F, Golfieri R, Morselli-Labate AM, Mastroroberto M, Badea RI, Piscaglia F.
    Eur Radiol; 2018 Sep 01; 28(9):3611-3620. PubMed ID: 29633000
    [Abstract] [Full Text] [Related]

  • 10. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J, Yin Z, Zhang Z, Fan D, Xia J, Han G.
    Int J Cancer; 2017 Jan 15; 140(2):390-399. PubMed ID: 27681592
    [Abstract] [Full Text] [Related]

  • 11. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
    Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    J Gastroenterol; 2014 Dec 15; 49(12):1578-87. PubMed ID: 24499826
    [Abstract] [Full Text] [Related]

  • 12. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
    Moschouris H, Malagari K, Gkoutzios P, Kalokairinou M, Stamatiou K, Chatzimichail K, Kornezos I, Karagiannis E, Kiltenis M, Papadaki MG.
    Med Ultrason; 2012 Jun 15; 14(2):87-94. PubMed ID: 22675707
    [Abstract] [Full Text] [Related]

  • 13. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G.
    Radiol Med; 2014 Apr 15; 119(4):215-21. PubMed ID: 24297581
    [Abstract] [Full Text] [Related]

  • 14. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Patchett N, Furlan A, Marsh JW.
    Jpn J Clin Oncol; 2016 Sep 15; 46(9):839-44. PubMed ID: 27317737
    [Abstract] [Full Text] [Related]

  • 15. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014 Sep 15; 32(6):733-9. PubMed ID: 25376291
    [Abstract] [Full Text] [Related]

  • 16. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
    Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Izumi N, Japanese Red Cross Liver Study Group.
    Liver Int; 2015 May 15; 35(5):1581-9. PubMed ID: 24836552
    [Abstract] [Full Text] [Related]

  • 17. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.
    J Clin Oncol; 2013 Oct 01; 31(28):3509-16. PubMed ID: 23980090
    [Abstract] [Full Text] [Related]

  • 18. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF.
    Radiology; 2015 Nov 01; 277(2):594-603. PubMed ID: 26069923
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Park JG.
    Clin Mol Hepatol; 2015 Sep 01; 21(3):287-94. PubMed ID: 26527250
    [Abstract] [Full Text] [Related]

  • 20. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.
    J Clin Oncol; 2013 Oct 01; 31(28):3517-24. PubMed ID: 23980084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.